PWM
MTCR

Prentice Wealth Management’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Prentice Wealth Management’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-750
Closed -$3K – 330
2021
Q3 		$3K Buy
+750
New +$2.34K ﹤0.01% 293

Other funds holding MTCR

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prentice Wealth Management's MTCR Position: Q4 2021 in Review

Prentice Wealth Management sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2021, closing a stake of 750 shares — an estimated $3K sold.

Prentice Wealth Management first reported a position in MTCR in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 31 funds tracked by Wall St. Rank hold MTCR as of Q4 2021.

  • Prentice Wealth Management reported no remaining Metacrine, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Prentice Wealth Management sold 750 Metacrine, Inc. Common Stock shares in Q4 2021, an estimated $3K.
  • Prentice Wealth Management first reported a position in Metacrine, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Prentice Wealth Management's Metacrine, Inc. Common Stock position peaked at $3K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2021.

Based on Prentice Wealth Management's 13F filing for Q4 2021, filed 31 Oct 2022.